One-year consolidation with Ponatinib 15 mg in chronic myeloid leukaemia on deep molecular response with Imatinib
Por:
Pérez-Lamas, L, Manzanares, M, Boluda, JCH, Montero, LFC, Casares, MTG, Ayala, R, Xicoy, B, Marin, FF, Ortí, G, Arias, RD, Prendes, SO, Lopez, RP, Mora, E, Nuño, CR, Velasco, AJ, Boqué, C, Pacho, MS, Lopez, JM, Carreño-Tarragona, G, Coiras, M and Garcia-Gutierrez, V
Publicada:
20 ene 2026
Resumen:
Tyrosine kinase inhibitors (TKIs) discontinuation is the standard option for patients with chronic myeloid leukaemia (CML) in deep molecular response (MR) with imatinib. This study aimed to evaluate the efficacy and safety of one year consolidation with ponatinib on treatment-free remission (TFR) rate. This was a multicenter open-label, single-arm, phase II, exploratory clinical trial including patients with CML treated >= 4 years with imatinib therapy, and MR4.0 >= 12 months. Patients entered the TFR phase after receiving ponatinib at 15 mg/day for one year. Twenty three patients received ponatinib and 19 completed consolidation. Among the patients with detectable BCR::ABL1, 70% deepened response. The 48-weeks MR4.0 rate was 68.4% (95%CI: 43.4-87.4). The 48-week TFR rate as classically defined was 73.7% (95% CI: 8 56.3-96.4). Five restarted TKIs and all regained MR. The most frequent adverse events (AEs) were constipation (34.8%), asthenia (30.4%) and myalgia (21.7%). Patients who remained relapse-free one year after ponatinib discontinuation exhibited higher levels of NK and NKT-like cells with degranulation capacity. Consolidation with ponatinib showed a high TFR rate and adequate safety, granting further research.
Filiaciones:
Pérez-Lamas, L:
Hosp Univ Puerta Hierro, Majadahonda, Madrid, Spain
Manzanares, M:
Inst Salud Carlos III, Natl Ctr Microbiol, Immunopathol & Viral Reservoir Unit, Majadahonda, Madrid, Spain
Boluda, JCH:
Hosp Clin Univ INCLIVA, Valencia, Spain
Montero, LFC:
HM Hosp CIOCC, Madrid, Spain
Casares, MTG:
Hosp Univ GC Doctor Negrin, Las Palmas Gran Canaria, Spain
Ayala, R:
Univ Complutense Madrid, Hosp Univ, Hosp Univ12 Octubre, I 12,CNIO,CIBERONC, Madrid, Spain
:
Univ Autonoma Barcelona, Inst Recerca Leucemia Josep Carreras, Hosp Univ Germans Trias & Pujol, Hematol Dept,Inst Catala Oncol, Badalona, Spain
Marin, FF:
Hosp Univ Morales Meseguer, Ctr Reg Hemodonac, IMIB Arrixaca, UCAM,CIBERER, Murcia, Spain
Ortí, G:
Hosp Univ Vall dHebron, Barcelona, Spain
Arias, RD:
Hosp Univ La Paz, IdiPAZ, Madrid, Spain
Prendes, SO:
Hosp Univ Gregorio Maranon, Madrid, Spain
Lopez, RP:
Hosp Univ Virgen Arrixaca, Murcia, Spain
Mora, E:
Hosp Univ & Politecn La Fe, Valencia, Spain
Nuño, CR:
Hosp Univ Reg Malaga, Malaga, Spain
Velasco, AJ:
Hosp Univ Reg Malaga, Malaga, Spain
Boqué, C:
Hosp Duran & Reynals, ICO, Barcelona, Spain
Pacho, MS:
Hosp Univ Salamanca, Salamanca, Spain
Lopez, JM:
Univ Complutense Madrid, Hosp Univ, Hosp Univ12 Octubre, I 12,CNIO,CIBERONC, Madrid, Spain
Carreño-Tarragona, G:
Univ Complutense Madrid, Hosp Univ, Hosp Univ12 Octubre, I 12,CNIO,CIBERONC, Madrid, Spain
Coiras, M:
Inst Salud Carlos III, Natl Ctr Microbiol, Immunopathol & Viral Reservoir Unit, Majadahonda, Madrid, Spain
Inst Salud Carlos III, Biomed Res Ctr Network Infect Dis, CIBERINFEC, Majadahonda, Madrid, Spain
Garcia-Gutierrez, V:
Univ Alcala, Hosp Univ Ramon y Cajal, IRYCIS, Madrid, Spain
Hosp Univ Ramon & Cajal, IRYCIS, Ctra Colmenar Viejo, Madrid 28034, Spain
Green Submitted, gold
|